Director Jason Aryeh filed a Form 144 notice on November 10, 2026, disclosing a proposed sale of 3,000 Class B common shares of Ligand Pharmaceuticals Inc. through Wells Fargo Clearing Services.
Key Highlights
- Proposed sale: 3,000 shares of Class B common stock with an aggregate market value of $960,084.19
- Original acquisition: The 3,000 shares were acquired via secondary market purchase on May 14, 2019, for cash
- Shares outstanding: 20,002,986 Class B common shares outstanding at the time of notice
- Approximate sale date: November 10, 2026, through Wells Fargo Clearing Services on Nasdaq
- Prior sales in past 3 months: Aryeh sold a combined 2,393 shares in four transactions between October 30 and November 4, 2026, generating gross proceeds of $761,744.06
- Relationship to issuer: Jason Aryeh is listed as a Director of Ligand Pharmaceuticals Inc.
Ligand Director Aryeh Discloses Proposed Class B Share Sale
According to the Form 144 filing, Jason Aryeh, a Director of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), notified the SEC of a proposed sale of 3,000 Class B common shares with an aggregate market value of $960,084.19. The shares are to be sold through Wells Fargo Clearing Services, located at 1 North Jefferson Avenue, St. Louis, MO 63103, on the Nasdaq exchange. The notice is dated November 10, 2026.
The filing states that the 3,000 shares subject to this notice were originally acquired through a secondary market purchase on May 14, 2019, with payment made in cash on that date. A remark in the filing notes that "shares were acquired between 05/14/2019 to 07/30/2019." At the time of the notice, Ligand Pharmaceuticals had 20,002,986 Class B common shares outstanding, according to the filing.
The filing also discloses sales made by Aryeh during the three months preceding the notice. On October 30, 2026, Aryeh sold 1,209 shares for gross proceeds of $385,185.47 and an additional 202 shares for gross proceeds of $64,738.00. On November 2, 2026, 700 shares were sold for $221,595.09, and on November 4, 2026, 282 shares were sold for $90,225.50. Combined, these four prior transactions totaled 2,393 shares and $761,744.06 in gross proceeds, as reported in the filing.
What Was Disclosed
Jason Aryeh, a Director of Ligand Pharmaceuticals Inc., filed a Form 144 notice proposing to sell 3,000 Class B common shares valued at $960,084.19, originally purchased in 2019, through Wells Fargo Clearing Services on Nasdaq on November 10, 2026.



Please wait processing your request...